What are the indications, contraindications, dosing options, and monitoring recommendations for testosterone replacement therapy in adult males with documented low serum testosterone?

Testosterone Replacement Therapy in Adult Males

Primary Indication and Recommendation

Testosterone replacement therapy should be considered primarily for men with documented low testosterone AND sexual dysfunction who desire improvement in sexual function, with intramuscular formulations preferred over transdermal due to equivalent efficacy at lower cost 1.

Indications

FDA-Approved Indications

Testosterone therapy is FDA-approved only for men with low testosterone due to identifiable organic causes (diseases of the hypothalamus, pituitary, or testes) 1. The FDA explicitly requires labeling stating products are NOT approved for age-related low testosterone alone.

Evidence-Based Clinical Indications

Primary indication:

• Men with age-related low testosterone (<320 ng/dL or <11.1 nmol/L) AND sexual dysfunction who want to improve sexual function 1
• Must include shared decision-making discussion of benefits, harms, costs, and patient preferences

NOT indicated for:

• Improving energy, vitality, physical function, or cognition in men with age-related low testosterone 1
• These symptoms lack sufficient evidence linking them to testosterone deficiency versus other age-related factors or comorbidities

Organic hypogonadism indications:

• Primary hypogonadism (testicular failure)
• Secondary hypogonadism (hypothalamic-pituitary disease)
• To induce and maintain secondary sex characteristics 2, 3

Contraindications

Absolute Contraindications

• Breast cancer 2, 3
• Prostate cancer 2, 3
• Palpable prostate nodule or induration 2, 3
• PSA >4 ng/mL (or >3 ng/mL in high-risk men: African-Americans or first-degree relatives with prostate cancer) without urological evaluation 3
• Hematocrit >50% 2, 3
• Severe heart failure (Class III or IV) 2

Relative Contraindications

• Severe lower urinary tract symptoms (IPSS >19) 2
• Untreated severe obstructive sleep apnea 2, 3
• Uncontrolled or poorly controlled heart failure 3

Dosing and Formulations

Preferred Route

Intramuscular testosterone is preferred over transdermal formulations when initiating therapy for sexual dysfunction because clinical effectiveness and harms are similar but costs are considerably lower 1.

Available Formulations

• Intramuscular injections (preferred)
• Transdermal (gels, patches)
• Buccal
• Nasal
• Subdermal pellets

Dosing Goal

Target mid-normal range testosterone levels during treatment 2, 3. Specific dosing depends on formulation chosen based on patient preference, pharmacokinetics, treatment burden, and cost 2, 3.

Monitoring Recommendations

Initial Assessment (Before Starting)

• Morning total testosterone level (measured twice on separate occasions to confirm diagnosis) 2, 3
• PSA and digital rectal examination in men >40 years 4
• Hematocrit (baseline) 2, 3
• Exclude contraindications listed above

During Treatment

Reevaluate symptoms within 12 months and periodically thereafter 1

Discontinue therapy if no improvement in sexual function after 12 months 1

Laboratory Monitoring (Men ≥40 years)

Measure at least annually:

• Serum testosterone levels
• Hematocrit
• PSA 5

Standardized Monitoring Plan

Men receiving testosterone should be monitored for:

• Symptom improvement
• Potential adverse effects
• Treatment adherence 2, 3

Critical Caveats

Age-Related Low Testosterone Controversy

The evidence for testosterone therapy in age-related low testosterone is low-certainty and based on conditional recommendations 1. The ACP guideline (2020) represents the most conservative, evidence-based approach and explicitly states this guideline does NOT address screening or diagnosis protocols 1.

Cardiovascular Safety

While older studies suggested increased cardiovascular risk, a large randomized trial demonstrated testosterone therapy does not increase risk of myocardial infarction or stroke, even in high-risk patients 5. However, severe heart failure remains a contraindication 2.

Diagnostic Threshold

No universally accepted testosterone threshold exists below which symptoms definitively occur 1. Syndromic low testosterone is defined as ≥3 sexual symptoms with total testosterone <320 ng/dL 1.

Common Pitfall

Many nonspecific symptoms (fatigue, mood changes, decreased muscle mass) attributed to low testosterone may actually result from chronic illnesses, medications, or aging itself rather than testosterone deficiency 1. Do not prescribe testosterone for these symptoms alone without documented sexual dysfunction.